What did those Alzheimer’s researchers lie about?
In: 24
I assume you’re talking about the FDA approval of the clinical research drug called aducanumab (Aduhelm).
In clinical trials, aducanumab reduced visible plaque in the brain, which is considered a ‘surrogate outcome’ or a test result with no real patient benefit.
In other words, Aducanumab did not actually have a noticeable effect on Alzheimer’s patient outcomes, but the drug was incorrectly touted by Biogen and Big Pharma as the future of Alzheimer’s disease treatment.
The thing is, my previous boss (pharmacist) told me that the drug could be potentially helpful for those who have very early onset of Alzheimer’s or other related dementia, but unfortunately it has no current scientific basis to have received FDA approval so quickly.
It seems like the FDA received incredible pressure to follow through with the passage of this drug when it shows marginal (if any) effect in patients. Very misleading all across the board.
Latest Answers